摘要
目的:研究酒石酸美托洛尔与硝苯地平联合对原发性高血压患者血压控制及生活质量的影响。方法:选择天津市蓟州区邦均医院2016年3月至2017年5月治疗的96例原发性高血压患者,随机数字表法分组,各48例。对照组给予硝苯地平治疗;观察组给予酒石酸美托洛尔+硝苯地平治疗。两组均持续用药2个月,统计对比两组临床治疗效果,并比较治疗前后两组血压[收缩压(SBP)、舒张压(DBP)]水平及生活质量综合评定问卷(GQOLI-74)评分变化。结果:观察组临床有效率93.75%(45/48)较对照组77.08%(37/48)高,差异有统计学意义(P<0.05);治疗后与对照组比较,观察组血压DBP、SBP水平较低,差异均有统计学意义(P<0.05);观察组治疗后G QOLI-74量表中躯体功能、心理功能、社会功能、物质生活状态各项评分较对照组高(P<0.05)。结论:酒石酸美托洛尔与硝苯地平联合治疗原发性高血压患者,可降低其血压,提高其生活质量,治疗效果较好,且安全性较高。
Objective To explore the effect of metoprolol tartrate combined with nifedipine on blood pressure control and quality of life in patients with essential hypertension. Methods： 96 patients with essential hypertension treated in our hospital from March 2016 to May 2017 were randomly divided into groups, with 48 cases in each. The control group was given nifedipine treatment, and the observation group was treated with metoprolol tartrate and nifedipine. The two groups were treated for 2 months. The effects of two groups of clinical treatments were compared, and the levels of blood pressure [systolic pressure （SBP）, diastolic pressure （DBP）] and quality of life questionnaire （GQOLI-74） were compared between the two groups before and after the treatment. Results： The clinical effective rate of the observation group was 93.75% （45/48）, which was significantly higher than that of the control group 77.08% （37/48） （P〈0.05）. After treatment, compared with the control group, the levels of blood pressure DBP and SBP were lower in the observation group, and the differences were statistically significant（P〈0.05）. The scores of somatic function, psychological function, social function and material life state of the GQOLI-74 scale in the observation group were higher than those in the control group after treatment（P〈0.05）. Conclusion： Metoprolol tartrate combined with nifedipine can reduce the blood pressure and improve the quality of life in patients with essential hypertension. The treatment effect is significant and the safety is high.
作者
苏春芳
尹力
SU Chun-fang;YIN Li(Department of Cardiology,State Hospital of Jizhou City,Tianjin,301901;Department of Cardiology,Second Hospital Af？liated to Tianjin Medical University,Tianjin,300222)
出处
《药品评价》
CAS
2018年第21期59-61,共3页
Drug Evaluation
